OncoCyte Co. (OCX) Short Interest Update

OncoCyte Co. (NYSEAMERICAN:OCX) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 330,835 shares, a growth of 58.5% from the November 15th total of 208,771 shares. Currently, 4.0% of the shares of the company are sold short. Based on an average daily volume of 39,702 shares, the short-interest ratio is currently 8.3 days.

A number of equities analysts recently commented on OCX shares. ValuEngine upgraded OncoCyte from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Zacks Investment Research cut OncoCyte from a “hold” rating to a “sell” rating in a report on Saturday, November 18th.

An institutional investor recently raised its position in OncoCyte stock. Broadwood Capital Inc. raised its position in shares of OncoCyte Co. (NYSEAMERICAN:OCX) by 17.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,596,680 shares of the biotechnology company’s stock after acquiring an additional 540,000 shares during the period. OncoCyte makes up approximately 4.5% of Broadwood Capital Inc.’s investment portfolio, making the stock its 5th largest position. Broadwood Capital Inc. owned about 11.48% of OncoCyte worth $27,155,000 at the end of the most recent reporting period.

OncoCyte (NYSEAMERICAN:OCX) opened at $6.00 on Thursday. OncoCyte has a 1-year low of $3.60 and a 1-year high of $7.95.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.truebluetribune.com/2017/12/14/oncocyte-co-ocx-short-interest-update.html.

OncoCyte Company Profile

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply